Novel derivative of alpha substituted 17 alpha substituted 17 beta-oh-19-norsteroid,its production, use thereof as drug and pharmaceutical composition containing the same
8 claims: 4 independent, 4 dependent
- 1PATENTANSPRÜCHE 1. Verbindung der Formel -11AT396787B in der R' eine Propylgruppe, eine 1-Propenylgruppe, eine Jodäthenylgruppe, eine Jodäthynylgruppe oder eine -CsC-C^HalpGruppe darstellt, in der Halj ein Chlor-, ein Fluor- oda ein Bromatom ist, sowie deren Additionssalze mit mineralischen oda organischen Säuren.
- 2Eine Verbindung da Fonnel (I) nach Anspruch 1:- 17Alpha-(3-Chlor 1-Propynyl) UBeta- 4-(Dimethylamino)Phenyl 17Beta Hydroxy estra-4,9-dien-3-on, - 1 IBeta- 4-(Dimethylamino)Phenyl 17Alpha-(3-Fluor 1-Propynyl) 17Beta-Hydroxy estra-4,9-dien-3-on, - 1 IBeta- 4-(Dimethylamino)phenyl 17Beta-Hydroxy 21-Jod 19-Nor 17alpha-pregna-4,9-dien-20-yn-3-on, - (E) UBeta- 4-(Dimethylamino)phenyl 17Beta-Hydroxy 21-Jod 19-Nor 17Alpha-pregna-4,9,20-trien-3-on, - (Z) UBeta- 4-(Dimethylamino)phenyl 17Beta-Hydroxy 21-Jod 19-Nor 17Alpha-pregna-4,9,20-trien-3-on, - UBeta- 4-(Dimethylamino)phenyl 17Beta-Hydroxy 17Alpha-[(Z)l-Propenyl] estra-4,9-dien-3-on, - 1 IBeta- 4-(Dimethylamino)phenyl 17 Beta-Hydroxy 17Alpha-Propyl estra 4,9-dien-3-on und - 17Alpha-(3-Brom 1-Propynyl) UBeta- 4-(Dimethylamino)phenyl 17Beta-Hydroxy estra-4,9-dien-3-on sowie ihre Additionsalze mit mineralischen oder organischen Säuren.
- 3Verwendung von Vabindungen der Formel (I) nach Anspruch 1 oder 2, die pharmazeutisch verträglich sind, als Medikament.
- 4Verwendung von Verbindungen der Fonnel (I) nach einem der Ansprüche 1 bis 3, die pharmazeutisch verträglich sind, als veterinärmedizinische Präparate.
- 5Verwendungvon (Z) 1 IBeta- 4-(Dimethylamino)phenyl 17Beta-Hydroxy 17Alpha- (Z) 1-Propenyl estra4,9-dien-3-on in veterinärmedizinischen Präparaten.
- 6Pharmazeutische Produkte, die als Wirkstoff mindestens eine der in Anspruch 3 definierten Substanzen enthalten.
- 7Veterinärmedizinische Präparate, die als Wirkstoff mindestens eine da in den Ansprüchen 4 oda 5 definierten Substanzen enthalten.
- 8Verfahren ziir Herstellung von Verbindungen der Formel (I) gemäß Anspruch 1, dadurch gekennzeichnet, daß a) zur Hasteilung von Verbindungen der Formel ’Ü2A) in da Halj ein Brom-, Chlor- oder Fluor-Atom darstellt, ein Bromier- oda Chlorier-Reagens, wie das Triphenylphosphin, mit Teträbromid oder Kohlenstofftetrachlorid in Gegenwart eines Lösungsmittels, wie etwa Tetrahydrofuran oder Methylenchlorid mit einer Verbindung der Fonnel -12AT396787B umsetzt, um die Verbindung der Formel (^yQ zu erhalten, in der Halj ein Brom- oder ein Chlor-Atom darstellt, wonach ein Reagens auf letztgenannte Verbindung einwirken gelassen wird, das Brom oder Chlor durch Fluor ersetzt, wie Cäsiumfluorid oder Kaliumfluorid, in Gegenwart eines Ringäthers 18-6 in Acetonitril, b) zur Herstellung υοπ Verbindungen der Formel in der die Doppelbindung E- oder Z-Konfiguration aufweist, ein Produkt der Formel (P 2 ) in derKeine geschützte Ketongruppe darstellt, zum Beispiel eineEthylendioxy-Gruppe, miteinem Reduktionsmittel, wie Tributylethanwasserstoff umgesetzt wird, und zwar unter Radikalbedingungen, entweder in Anwesenheit von z. B. Azoisobutyronitril, um eine Doppelbindung derE-Konfigurationzu erhalten, oder in einem aprotischen polaren Lösungsmittel, wie z. B. Hexamethylphosphotriamid, um eine Doppelbindung der Z-Konfiguration zu erhalten, daß dann ein Jodisierungsmittel, wie N-Jodsuccinimid zugesetzt wird, um, nach Entfernung der Schutzgruppe, die Veibindungen der Formel (Ijg) zu erhalten, in denen die Doppelbindung E- oder Z-Konfiguration aufweist, c) zur Herstellung einer Verbindung der Formel -13AT396787B mit einem Jodierungsmittel, wie N-Jodsuccinimid, in Gegenwart eines Silbersalzes, wie des Silberkarbonats oder -nitrats, umsetzt, um die Verbindung der Formel (I 2 q) zu erhalten, d) zur Herstellung einer Verbindung der Formel »^d) in der die unterbrochene Linie darauf hinweist, daß es zwischen den Kohlenstoffen eine einfache oder eine Doppelbindung (Z) gibt, die Verbindung der Formel (P4) mit Wasserstoff in Gegenwart eines Katalysators, wie Palladium auf Bariumsulfat, teilweise durch ein Amin, wie Pyridin oder Triethylamin, versetzt (vergiftet), umsetzt, um als Hauptprodukt die Verbindung der Formel (Ι 2 θ) zu erhalten, in der der unterbrochene Strich auf das Vorhandensein einer zweiten Bindung (Z) hinweist, und als Nebenprodukt das Produkt, bei dem der unterbrochene Strich das Vorhandensein einer einfachen Bindung aufzeigL
Independent claims8
179 paragraphs in 12 sections, as filed
(54) NEW DERIVATIVES OF THE 17BETA-0H 19-NOR-STEROIDS SUBSTITUTED TO 17ALPHA, THEIR MANUFACTURING PROCESS, THEIR APPLICATION AS MEDICAMENTS AND PHARMACEUTICALS IN WHICH THEY ARE CONTAINED (57) The invention relates to novel compounds I in which R 'represents a propyl group, a 1-propenyl group, a iodoethyl group, an iodoethynyl group or a - C = C-CH 2 Hai group in the shark
Chlorine, a fluorine or a bromine atom, as well as their addition salts with mineral or organic acids, which have antiprogestomimetic activity, and to processes for their preparation.
<img file="AT396787B_D0001.tif" />
CD
AT 396 787
MR 5078013
The invention relates to novel derivatives of 17-beta-OH-19-nor-steroids substituted at 17Alpha, their method of preparation, their use as medicaments and pharmaceutical products in which they are contained.
Subject matter of the invention are the compounds da formula
<img file="AT396787B_D0002.tif" />
Here, R 'represents a propyl group, a 1-propenyl group, an iodo-phenyl group, an iodoethynyl group or a -CsC-C ^ Hali group, in which Hai represents a chlorine, a fluorine or a bromine atom, as well as their addition salts organic or mineral acids.
When R * represents an iodoethenyl group, the double bond has E or Z configuration.
If R * represents a 1-propenyl group, the double bond has Z configuration.
The invention thus relates in particular to any compound of the above-defined formula (I), as indicated below:
17Alpha- (3-chloro-1-propynyl) HBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy-estra-4,9-dien-3-one,
- llBeta- <4- (dimethylamino) phenyl> 17Alpha- (3-fluoro-1-propynyl) -17Beta-hydroxy-estra-4,9-dien-3-one,
1 IBeta- <4- (dimethylamino) phenyl> 17beta-hydroxy 21-iodo 19-nor 17alpha-pregna-4,9-dien-20-yn-3-one,
(E) llBeta- <4- (dimethylammo) phenyl> 17beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna-4,9 / 20-triene-3one,
(Z) IIBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna4,9jZO-triene-3-one,
- llBeta- <4- (dimethylamino) phenyl> 17beta-hydroxy 17Alpha - [(Z) 1-propenyl] estra-4,9-dien-3-one,
- llBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy 17Alpha-propyl estta 4,9-dien-3-one and
- 17Alpha- (3-bromo 1-propynyl) llBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy-estra-4,9-dien-3-one and their addition salts with mineral or organic acids.
Among the most preferred compounds of the invention, insbesondoe should be mentioned:
- llBeta- <4- (dimethylamino) phenyl> 17Alpha- (3-fluoro-1-propynyl) -17Beta-hydroxy-estra-4,9-dien-3-one,
(Z) IIBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy-21-iodo 19-Nor 17Alpha-pregna-4,9,20-triene-3-one,
- llBeta- <4- (dimethylamino) phenyl> 17beta-hydroxy 17Alpha> (Z) 1-propenyl> estra-4,9-dien-3-one.
It should be mentioned at this point that similar relationships z. B. from EP-A2 57115 da patent owner have become known. However, it has been found that very minor differences in molecular structure between the compounds of this prior art and those of the present invention lead to unexpected and blatantly high differences in their effectiveness. As a typical example, the following vague is picked out:
It is the product A according to the later following Example 6 of the present invention with a structurally almost identical product according to Example 22 of EP-A2 mentioned above:
The two compounds have the following formulas:
-2AT396787B
Product Α according to the invention
<img file="AT396787B_D0003.tif" />
t l-propenyl
Product according to EP-A2
<img file="AT396787B_D0004.tif" />
0‘
In a pharmacological comparison, it is found that in the conditions of determination of compound affinity for the female uterine receptor, the compound according to EP-A2 and those according to the present invention have substantially different values of relative affinity of binding (ARL) after 24 hours :
Product A: 387 (about 1.7 times higher than EP-A2 product)
EP-A2 Product 220
This difference is not only highly significant, but also completely unexpected, because the two compounds actually differ from each other only in terms of the position of the double bond in the side chain.
This effect, as just explained, represents a clear indication of the value of the bonds according to the invention in comparison to those of the prior art.
As addition salts of the products of the formula (I) with acids, in particular the chlorohydrates and the methanesulphonates are to be mentioned. The products according to the invention as well as their addition salts with the pharmaceutically acceptable acids are particularly noteworthy from the pharmacological point of view; in particular, they have a remarkable antiglucocorticoid property. The products according to the invention also have androgenic or antiandrogenic properties.
The examination of the products also revealed a particularly antiprogestomimetic effect.
The products according to the invention and their addition salts with pharmaceutically acceptable acids can therefore be used mainly to combat the side effects of glucocorticoids; they are moreover suitable for use in combating the disorders due to hypersecretion of the glucocorticoids and in particular of the altem in general and especially of low blood pressure, arteriosclerosis, osteoporosis, diabetes, obesity and immunity weakness and insomnia in particular ,
The compounds of the formula (I) according to the invention, as well as their addition salts with pharmaceutically acceptable acids which possess antiprogestomimetic properties, can also be used for the preparation of the contraceptive; they can also be used to combat hormonal disorders and, moreover, can be used in the treatment of hormone-dependent cancers.
The compounds of formula (I) according to the invention as well as their addition salts with pharmaceutically acceptable acids can have antiprogestomimetic properties and can thereby be used in the treatment of amenorrhoea and dysmenorrhoea and luteal complaints.
-3AT396 787B
The invention thus relates, as a medicament, to the compounds of the formula I which are pharmaceutically acceptable, ie non-toxic in the doses used, and also their addition salts with the pharmaceutically acceptable acids.
In the context of medicaments, the invention relates above all to the preferred compounds mentioned above, namely the pharmaceutically acceptable compounds of Examples 2, 5 or 6 (compound A).
The dosage will vary depending on the disease to be treated and the type of administration; for example, it may vary between 10 mg and 1 g, but most often between 100 mg and 1 g per day for adults and oral ingestion.
The products of the present invention, as well as their addition salts with pharmaceutically acceptable acids having antiprogestomimetic properties, can also be used as abortifacients in veterinary medicine, especially for bitches and cats.
The invention accordingly relates, as animal medicament, to the compounds of formula (I) as well as their addition salts with pharmaceutically acceptable acids.
In particular, the invention relates, as animal medicament, to the preferred products mentioned above, in particular the 1 IBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy 17Alpha- <(Z) 1-propenyl> estra-4,9-dien-3-one ,
The dosage varies according to the disease and the animal to be treated.
It may be from 3 to 5 mg / kg live weight, at 1.2 or 3 peaks in 24 hour intervals, for example in the bitch 5 mg / kg live weight in 2 syringes at 24 hour intervals with the product of Example 6 (product A) ,
The compounds of the formula (I) according to the invention and their salts described above can be used to prepare pharmaceutical products containing as active substance at least one of the substances mentioned. The compounds of the formula (I) according to the invention and their salts can be administered by administration via the digestive apparatus, parenterally or locally. They may be prescribed in the form of simple or dragee-shaped tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels prepared by the usual methods.
The active ingredient can be introduced there by means commonly used in the pharmaceutical excipients, wieTalcum, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous excipients, animal or vegetable fats, paraffin derivatives, glycols, various wetting, dispersing or emulsifying Fabrics, preservatives.
The invention also relates to the pharmaceutical compounds which include as active ingredient at least one substance of the formula (I) according to the invention, or one of the addition salts with pharmaceutically acceptable acids.
Furthermore, the invention relates to pharmaceutical compounds for the treatment of animals, wherein as active ingredient at least one substance according to the invention of formula (I) is contained or one of the addition salts with pharmaceutically acceptable acids.
In particular, the invention relates to veterinary medicaments containing as the main active ingredient 1 IBeta- <4 (dimethylamino) phenyl> 17beta-hydroxy 17 alpha- <(Z) 1-propenyl> estra-4,9-dien-3-one.
The invention also provides a preparation process for compounds of the formula (I), which is characterized in that
a) for the preparation of compounds of the formula
<img file="AT396787B_D0005.tif" />
wherein Halj represents a bromine, chlorine or fluorine atom, a brominating or chlorinating reagent, such as the triphenylphosphine, with tetrabromide or carbon tetrachloride in the presence of a solvent, such as tetrahydrofuran or methylene chloride, with a compound of the formula
-4AT396787B
<img file="AT396787B_D0006.tif" />
reacted to the compound of formula (I<sub>2</sub>in which Halj represents a bromine or a chlorine atom, after which a reagent is allowed to act on the latter compound which replaces bromine or chlorine with fluorine, such as cesium fluoride or potassium fluoride, in the presence of a ring ether 18-6 in acetonitrile,
b) for the preparation of Vabindungen the formula
<img file="AT396787B_D0007.tif" />
'@ 2β) in that the double bond has E or Z configuration, a product of the formula
<img file="AT396787B_D0008.tif" />
. (P<sub>2</sub>) in the unprotected ketone group represents, for example, an ethylenedioxy group reacted with a reducing agent such as tributyl-hydrogenane under radical conditions, either in the presence of e.g. Azoisobutyronitrile to contain a double bond of the E configuration, or in an aprotic polar solvent such as e.g. B. Hexamethyl phosphotriamide to obtain a double bond of the Z configuration, then an iodization agent, such as N-iodosuccinimide, is added to give, after removal of the protective group, the compounds of formula (I<sub>2</sub>g) in which the double bond has E or Z configuration
c) for the preparation of a compound of the formula
<img file="AT396787B_D0009.tif" />
-5AT396787B
<img file="AT396787B_D0010.tif" />
with an iodizing agent, such as N-iodosuccinimide, in the presence of a silver salt, such as the silver carbonate or nitrite, to obtain the compound of formula (^ q),
d) for the preparation of a compound of the formula
<img file="AT396787B_D0011.tif" />
in which the broken line indicates that there is a single or double bond (Z) between the carbons, the compound of the formula
<img file="AT396787B_D0012.tif" />
with hydrogen in the presence of a catalyst, such as palladium on barium sulfate partially by an amine such as pyridine or triethylamine tri (added), reacted as the main product Vabindung da formula (I<sub>2D</sub>), in that the dashed line indicates the presence of a second bond (Z) and, as a by-product, the product in which the dashed line indicates the presence of a simple bond
The product Pj is described in FR-PS 2 566 779, the products P<sub>2</sub> and P3 are in EP-A-0 057115, the product P<sub>4</sub> is described in FR-PS 2 497 807.
The products of formula (I) are included in the general formula of EP-A-0057115, without, however, being described there.
The following examples explain the invention without restricting it.
-6AT396787B
example 1
17Alpha- (3-chloro-1-propynyl) II-beta- <4- (dimethylamino) phenyl> 17Beta-hydroxyestra4,9-dien-3-one. 800 mg of compound IIBeta- <4- (dimethylamino) phenyl> 17BetaHydroxy 17Alpha- (3-hydroxy-1-propynyl) estra-4,9-dien-3-one described in FR-PS 2 566 779 are dissolved in 8 ml of tetrahydrofuran and Dissolve 8 ml of carbon tetrachloride. Add 950 mg of triphenylphosphine and stir at 90 ° C for 3 h. A small insoluble residue is filtered out and the filtrate is evaporated to dryness. This gives 1.40 g of the crude product. The product is purified by chromatography on a (50/50) silicon column eluting with a mixture of petroleum ether (b.p. 40-70 ° C) -ethyl acetate. 420 mg of pure chlorinated product are obtained in the form of solid crystals. Melting point = 238 ° C.
IR spectrum fCHCl3)
OH: 3600 cm ·<sup>1</sup>
C = O conjugate 1655 cm '<sup>1</sup>
C = C conjugated and aromatic: 1612/1562/1518 cm '<sup>1 </sup>Example 2 llBeta-4- (dimethylamino) phenyl 17Alpha- (3-Fluoro-1-Propynyl) 17Beta-hydroxy-estra-4,9-dien-3-one. 313 mg of the compound 17Alpha- (3-chloro-1-propynyl) -lBeta- [4- (dimethylamino) -phenyl] 17Beta-hydroxy-estra-4,9-dien-3-one are dissolved in 10 ml of dry acetonitrile with 600 mg of ring ether 18- 6 stirred warming to 90 ° C in an inert atmosphere. After 23 h reflux, the solvent is evaporated and the residue is taken up in water and extracted with chloroacetate After washing with brine and drying on magnesium sulfate, the organic phase is evaporated to give 322 mg of crude fluorinated product The crude product is purified by chromatography on silica column with eluted with a mixture of methylene chloride / ethyl acetate 90/10 79 mg of pure product are obtained in a mixture of methylene chloride and Isopropyl ether is recrystallized to obtain 55 mg of the desired product. Melting point = 234-235 ° C.
IR spectrum ('CHCIA
OH: 3600 cm '<sup>1</sup>
C = O conjugate: 1655 cm ·<sup>1</sup>
C = C conjugated and aromatic: 1612/1562/1568 cm '<sup>1 </sup>Example 3 II Beta- <4- (dimethylamino) phenyl> 17beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna-4,9-dien-20-yn-3-one Dissolve 975 mg of II-beta- [4- (dimethylamino ) phenyl] 17beta-hydroxy 19-nor 17Alpha-pregna-4,9-dien20-yn-3-one in 20 ml of acetone, adds 650 mg of silver carbonate, further 450 mg of N-iodosuccinimide. The mixture is stirred for 4 h, then poured into an aqueous solution of 10% sodium thiosulfate and extracted by means of methylene chloride. The organic phase is washed with water, dried and evaporated to dryness. 1.2 g of crude product are obtained an ethyl acetate-cyclohexane mixture (6-4) is eluted; 390 mg of the desired product and 760 mg of mixture, which is chromatographed from silicon and eluted with a hexane-ether mixture (3-7), to give 530 mg of the desired product The 920 mg of the product obtained are crystallized in ether and 730 mg of the product (melting point = 210 ° C), further 79 mg of additional product from the stock solutions.
IR spectrum (CHCty OH: 3598 cm<sup>4</sup>
C = C: 2174 cm<sup>4</sup>
Dienon: 1654 cm *<sup>1</sup>
Aromatic: 1612/1562/1518 cm<sup>4 </sup>Example 4 (E) II Beta- <4- (dimethylamino) phenyl> 17beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna-4,9J20-triene-3-ai
Level A;
(E) (1,2-Ethanediyl) cyclic acetal of 5Alpha, 17beta-dihydroxy 1 lBeta- <4- (dimethylamino) phenyl> 21 iodo 19-Nor 17Alpha-pregna-9,20-dien-3-one.
-7AT396787B
1) Dissolve 1.5 g of (1,2-ethanediyl) cyclic acetal of 5Alpha, 17Beta-dihydroxy llBeta- [4 (dimethylamino) phenyl] 19-nor 17Alpha-pregna-9-en-20-yn-3 in 30 ml of anhydrous tetrahydrofuran, add 8 ml of tributylethane hydride and 300 mg of azoisobutyronitrile and heat the mixture under reflux for 50 min. The mixture is then concentrated under reduced pressure and the residual oil dissolved in methylene chloride is chromatographed on silica. The mixture is eluted with a cyclohexane-ethyl acetate mixture (7-3) to obtain 2.96 g of tributylstannylvinyl intermediate derivative
2) Dissolve in 30 ml of anhydrous tetrafuran, add 900 mg of N-iodosuccinimide. After 25 min of reaction, the mixture is poured into a 10% aqueous sodium thiosulfate solution and extracted by means of methylene chloride. The organic phase is washed in water, dried and evaporated to dryness. The residue is thickened in reflux in isopropyl ether, iced and dried. This gives 1.66 g of the desired product, melting point = 246 ° C.
IR spectrum (CHCty Free OH: 3600 cm<sup>1</sup>
OH in 5: 3500 cm<sup>1</sup>
Aromatic substances: 1613/1517 cm '<sup>1</sup>.
Level B;
(E) IIBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna-4,9,20-trien-3-one. Dissolve 1.66 g of the product obtained in A in 16 ml of methanol and 16 ml hydrochloric acid 2N. The solution is allowed to stand at room temperature for hours, the reaction mixture is poured into an aqueous solution of soda bicarbonate, filtered, and the precipitate redissolved in methylene chloride. Dry the organic phase and evaporate under reduced pressure. The residue is chromatographed on silica, eluted with a cyclohexane / ethyl acetate mixture (7-3) to obtain 1.28 g of the desired crude product. After dissolution in methylene chloride, concentration and crystallization by the addition of ether, to obtain 1.125 g of the desired product, mp = 236 ° C, after recrystallization in ethanol.
IR spectrum fCHCIT)
Dienon C = O: 1654 cm<sup>1</sup>
C = C: 1612 cm<sup>1</sup>
Aromatic substances: 1518 cm<sup>1 </sup>OH: 3600 cm<sup>1</sup>
Example 5 (Z) II Beta- <4- (dimethylamino) phenyl> 17beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna-4,9,20-trien-3-one
Level A:
(Z) (1,2-Ethanediyl) cyclic acetal of 5Alpha, 17Beta-dihydroxy llBeta- <4- (dimethylamino) phenyl> 21-tributylstannyl 19-Nor 17Alpha-pregna-9,20-dien-3-one.
Dissolve 477 mg (1,1-ethanediyl) cyclic acetal of 5Alpha, 17beta-dihydroxy llBeta- <4 (dimethylamino) phenyl> 19-Nor 17-alpha-pregna-9-en-20-yn-3-one in 5 ml of hexamethylphosphoric triamide, adds 2.6 ml of tin tributyl hydride in inert atmosphere and heated to 70 ° C for 25 h. It is then cooled, dissolved in water and extracted by means of ethyl acetate. The organic phase is washed in water, dried and concentrated to dryness. The residue is chromatographed on silica eluting with a mixture of petroleum ether (b.p. 40-70 ° C) and ether (6-4), yielding 214 mg of the isomer E, 135 mg of isomers E and Z isomers, and 346 mg of the desired isomer (Z).
Level B:
(Z) 1 IBeta- <4- (dimethylamino) phenyl> 17beta-hydroxy 21-iodo 19-Nor 17Alpha-pregna-4,9,20-trien-3-one.
Dissolve 47 g of the isomer (Z) in 30 ml of tetrahydrofuran obtained as described under Write 5. Add 520 mg of N-iodosuccinimide with shaking. After 30 min at room temperature, the reaction mixture is poured into an aqueous sodium thiosulfate solution and extracted by means of ethyl acetate. The organic phase is washed in water, dried and concentrated to dryness. 10 ml of methanol are added to the resulting residue with 10 ml of hydrochloric acid 2N and allowed to react for 1 h. Alkalize with sodium bicarbonate solution and extract with methylene chloride. The organic phase is washed with water, then concentrated to dryness to give 136 g of crude product. The residue is chromatographed on silica with a cyclohexane-8AT396787B
Ethyl acetate mixture eluted and excreted 600 mg of the desired product. Melting point = 178 ° C, after crystallization in ether.
IR spectrum / CHCU)
Range C = 0:
C = C:
Aromatic substances: OH:
1650 cm'<sup>1 </sup>1612 cm'<sup>1 </sup>1518 cm<sup>1</sup>
3590 cm'<sup>1</sup> and 3540 cm '<sup>1</sup>
Example 6 (Z) UBeta- <4- (dimethylamino) phenyl> 17beta-hydroxy 17Alpha <(Z) 1-propenyl> estra-4,9-dien-3-one (product A) and IIBeta- <4- (dimethylamino ) Phenyl> 17Beta-hydroxy 17Al-propyl-estra-4,9-dien-3-one (product B) e llBeta- <4- (dimethylamino) phenyl 17Beta-hydroxy 17Alpha- (1-propynyl) estra-4,9- dien-3-on will be in 50 cm<sup>3</sup> Ethanol and 1 cm<sup>3</sup> Triethylamine dissolved; then 75 mg of 10% palladium hydroxide is added to barium sulfate. The mixture is hydrogenated at normal temperature and stopped after 55 cm<sup>3</sup> Hydrogen were absorbed. The catalyst is filtered off, rinsed with ethanol, then the solvents are evaporated. This gives 1076 g of the crude product, which is chromatographed on a column of silica (extractant cyclohexane-ethylacetate 70-30). You get one after the other:
- 92 mg (Z) 1 IBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy 17Alpha- <(Z) 1-propenyl> estra-5 (10) en-3-one (Rf: 0.40).
- 568 mg (7/) llBeta- <4- (dimethylamino) phenyl> 17Beta-hydroxy 17Alpha- <(Z) 1-propenyl> esira-4,9-dien-3-one (Rf: 0.27) (product A) , 59mgllBeta- <4- (dimethylamino) phenyl> 17Beta-Hydroxyl 7α-Propylestra-4,9-dien-3-one (Rf: 0/24) (product B).
Physicochemical constants of product A
Analysis: - C29H37NO2 = 431.63
Calculated: Get: ''
C% 80.70 8034
H% 8.64 8.7
N% 3.25 3/2
IR spectrum fCHCl-ö
OH at:
C = O and C = C conjugate aromatic substances:
3608 cm'<sup>1 </sup>1654/1612 cm '<sup>1 </sup>1580/1518 cm '<sup>1</sup>
UV-Soektrum (EtOH)
Max 258nm = 17900
Max 303nm = 22700 + HCl 0, lN max = 301nm 21300
Physicochemical constants of product B
IR spectrum (CHCl3)
OH at 3615 cm '<sup>1</sup> C = O / C = C conjugated 1654/1612 cm '<sup>1 </sup>Aromatic 1560/1518 cm<sup>1</sup> '
Example 7
17alpha (3-bromo 1-propynyl) ll-beta- <4- (dimethylamino) phenyl> 17beta-hydroxy-estra-4,9-dicn-3-one 600mg of llBeta- <4- (dimethylamino) phenyl> 17beta-hydroxy 17Alpha - (3-hydroxy-1-propynyl) estra-4,9-dien-3-one are dissolved in 6 ml of methylene chloride with 491 mg of carbon tetrabromide. The solution is cooled to -10 ° C. Then a solution of 531 mg of triphenylphosphine in 3 ml of methylene chloride added The mixture is stirred for 20 min at -10 ° C then it is left unchanged a column of 15 g of silicon distributed and eluted with a mixture of petroleum ether (b.p. 40-70 ° C) and ethyl acetate 50/50. One holds 384 mg of pure bromine substance in the form of solid crystals.
-9AT396787B
pharmaceutical products
Make tablets according to the following formulation:
Compound from example 6 (product A) ......................................... ................................. 200 mg
- Carrier for a finished tablet ............................................ .............................. 350 mg (vehicles: talc, starch, magnesium stearate).
veterinary medication
An injectable solution was prepared which corresponds to the following formulation:
Compound from example 6 (product A) ......................................... ................................. 100 mg
- Ethanol ................................................ .................................................. .......................... 03 ml
- Peanut oil................................................ .................................................. ................ qsp 3 ml
Pharmacological examination of the products according to the invention
1 / Examination of the action of the products according to the invention on hormonal receptors:
Receptor progestogen of the uterus of the rabbit:
Non-sexually mature women weighing 1 kg will be exposed to an application of 25 g estradiol on the skin. 5 days after this treatment, the animals are killed, the uterus is removed, weighed and homogenized at 0 ° C, using a Potter Teflon glass in a buffered solution TS (Tris 10 mM, sucrose 0.25 M, HCl pH 7.4) (1 g tissue per 50 ml TS). The homogeneous mixture is then ultracentrifuged at 0 ° C (105,000 gx 90 min). The aliquots of the resulting supernatants were placed in the incubator at 0 ° C for a period of time t, at constant concentration (T) of the tritiated product R (17,21-dimethyl 19-nor 4,9 pregnadiene 3,20-dione ), with increasing concentrations (0- 2500.10<sup>9</sup> M) cold product R or cold progesterone, or cold product to be tested. The concentration of the tritiated product R (B) is then measured at each introduction into the incubator by means of the dextran carbon absorption technique.
Glucocorticoid receptor of the rat thymus gland
Male adrenals are excised from male Sprague-Dawley EOPS rats weighing 160-200 g. 4-8 days after this operation, the animals were calved and their thymus calves calved and at 0 ° C in a buffered solution Tris 10 mM, sucrose 0.25 M, dithiothreitol 2 mM, HCl pH 7.4, using a Potter- Polytetrafluoräthylen glass (1 g tissue for each 10 ml TS) homogenized. The homogenized mixture is then ultracentrifuged (105,000 x 90 mm) at 0 ° C. The aliquots of the resulting supernatants are placed in the incubator at 0 ° C for a given time (t), at constant concentration (T) of the tritiated dexamethasone, at increasing concentrations (0 - 2500.10 'M) of dexamethasone or cold dexamethasone of the cold product to be examined. The concentration of the tritiated dexamethasone treated (B) is then measured upon introduction into the incubator by the carbon-dextran absorption technique.
Calculation of Relative Link Affinity
The calculation of the relative binding affinity is the same for all receptors. B
The following two curves are drawn: the percentage of tritium-treated hormone in-dependent on the logarithm of the concentration of the cold reference hormone and, depending on the logarithm, the concentration of the cold test-product. T
BBB
The right side of the equation is determined r<sup>0</sup>= (- max + -min) / 2, where - max = percentage of TT T tritiated hormone on incubation with this hormone treated with tritium concentration (T).
Bmin = percentage of tritiated hormone bound on incubation with T
Concentration (T) of tritiated hormone in the presence of a large excess of cold hormone (2500.10<sup>9</sup> M).
The intersections of the right side Ι ^ θ with the curves allow to estimate the concentration of the cold reference 10AT396787B hormone (CH) as well as the tested cold product (CX), which delay the connection of the tritium-treated hormone with the receptor by 50% ,
The relative binding affinity (ARL) of the test product is determined by the equation:
(CH)
ARL = 100 (CX)
The following results were achieved:
<td rowspan="2">Products from the examples</td><td rowspan="2">In the incubator at Time spent 0 ° C</td><td colspan="2">progestogen</td><td colspan="2">glucocorticoid</td>
<td>2h</td><td>24 hours</td><td>4h</td><td>24 hours</td>
<td> 1</td><td></td><td> 72</td><td> 286</td><td> 139</td><td> 159</td>
<td> 5</td><td></td><td> 41</td><td> 184</td><td> 145</td><td> 113</td>
<td>6 (product A)</td><td></td><td> 96</td><td> 491</td><td> 147</td><td> 115</td>
Abortion effect in the bitch
Preparation of a solution of the test product
250 mg of the test product are dissolved in 1 ml of methylene chloride, then 1 ml of this solution is dissolved in sesame oil until 250 ml of the final solution are obtained.
Echography is used to determine the gestational age of bitches, which must be 16 months to 4 years old, and the gestation period, which may be between 25 and 40 days.
The test product is then subcutaneously administered in a solution as indicated above at a dose of 5 mg / kg, with 2 syringes being given at an interval of 24 hours.
until 10 days after administration of the last syringe, a control is done.
Days after the injection of the product according to Example 6 (product A), 66% of the cases experience abortion.
Days after injection of the product according to example 6 (product A) one can detect a complete abortion in all animals of the group.
Abortion on hesin lOTage after hopping, the hens are given a subcutaneous injection with the test product, which must be in a solution as indicated above, at a dose of 4 mg / kg and 5 mg / kg. 10 days after this treatment, the animals are killed; the number of abortions detected at autopsy is recorded.
Complete abortion is noted in all animals of the group upon injection of the product of Example 6 (product A), both at a dose of 4 mg / kg and at 5 mg / kg.
Contents12
12 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12
Every citation, both waysCites: the store holds 4 of 5
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP0057115A2 | Cites | European Patent Office (EPO) | Search report |
| EP0129499A2 | Cites | European Patent Office (EPO) | Search report |
| EP0277676A1 | Cites | European Patent Office (EPO) | Search report |
| US4634695A | Cites | United States of America | Search report |
| CHEM.ABS. 106, 129 694R | Non-patent | – | Search report |
101 members in 32 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 8718376 | France | A | |
| 8718376 | France | A | |
| 1837687 | – | – | – |
| FR19870018376 | – | – | – |
Members101
| Document | Office | Kind | |
|---|---|---|---|
| PT74263A | Portugal | A | |
| IE820044L | Ireland | L | |
| DK4082A | Denmark | A | |
| FI820042L | Finland | L | |
| AU7929682A | Australia | A | |
| FR2497807A1 | France | A1 | |
| EP0057115A2 | European Patent Office (EPO) | A2 | |
| EP0057115A3 | European Patent Office (EPO) | A3 | |
| JPS57168000A | Japan | A | |
| ZA8231B | South Africa | B | |
| ES508588A0 | Spain | A0 | |
| ES8305786A1 | Spain | A1 | |
| US4386085A | United States of America | A | |
| FR2497807B1 | France | B1 | |
| ES517764A0 | Spain | A0 | |
| ES8401498A1 | Spain | A1 | |
| FR2528434A1 | France | A1 | |
| EP0097572A1 | European Patent Office (EPO) | A1 | |
| KR840000581A | Republic of Korea | A | |
| JPS5946299A | Japan | A | |
| US4447424A | United States of America | A | |
| EP0110434A1 | European Patent Office (EPO) | A1 | |
| HU185158B | Hungary | B | |
| EP0057115B1 | European Patent Office (EPO) | B1 | |
| AT12239T | Austria | T | |
| ATE12239T1 | Austria | T1 | |
| DE3262580D1 | Germany | D1 | |
| US4519946A | United States of America | A | |
| FR2528434B1 | France | B1 | |
| CA1193246A | Canada | A | |
| US4547493A | United States of America | A | |
| CA1199907A | Canada | A | |
| AU550334B2 | Australia | B2 | |
| AU5123685A | Australia | A | |
| EP0196707A1 | European Patent Office (EPO) | A1 | |
| EP0110434B1 | European Patent Office (EPO) | B1 | |
| EP0097572B1 | European Patent Office (EPO) | B1 | |
| AT23167T | Austria | T | |
| AT23344T | Austria | T | |
| ATE23167T1 | Austria | T1 | |
| ATE23344T1 | Austria | T1 | |
| DE3273985D1 | Germany | D1 | |
| DE3367396D1 | Germany | D1 | |
| US4634695A | United States of America | A | |
| US4634696A | United States of America | A | |
| CA1220780A | Canada | A | |
| KR870001936B1 | Republic of Korea | B1 | |
| SG45987G | Singapore | G | |
| IE52595B1 | Ireland | B1 | |
| AU579211B2 | Australia | B2 | |
| SU1447289A3 | Soviet Union (until 1991) | A3 | |
| IT8848730A0 | Italy | A0 | |
| IT8848730D0 | Italy | D0 | |
| SE8804692D0 | Sweden | D0 | |
| FI77872B | Finland | B | |
| GB8830380D0 | United Kingdom | D0 | |
| FI77872C | Finland | C | |
| LU87417A1 | Luxembourg | A1 | |
| SE8804692L | Sweden | L | |
| FR2625505A2 | France | A2 | |
| DE3844408A1 | Germany | A1 | |
| NL8803196A | Netherlands (Kingdom of the) | A | |
| GB2213484A | United Kingdom | A | |
| JPH01213296A | Japan | A | |
| EP0196707B1 | European Patent Office (EPO) | B1 | |
| AT46702T | Austria | T | |
| ATE46702T1 | Austria | T1 | |
| DE3380628D1 | Germany | D1 | |
| JPH01279897A | Japan | A | |
| ES2012197A6 | Spain | A6 | |
| FR2640977A2 | France | A2 | |
| JPH0234958B2 | Japan | B2 | |
| US4978657A | United States of America | A | |
| CH676852A5 | Switzerland | A5 | |
| US5006518A | United States of America | A | |
| FR2625505B2 | France | B2 | |
| IL65680A | Israel | A | |
| US5043332A | United States of America | A | |
| GB2213484B | United Kingdom | B | |
| CA1303025C | Canada | C | |
| IT1235358B | Italy | B | |
| JPH0443077B2 | Japan | B2 | |
| JPH0466879B2 | Japan | B2 | |
| BE1004905A4 | Belgium | A4 | |
| ATA318788A | Austria | A | |
| DK166680B1 | Denmark | B1 | |
| AT396787BThis record | Austria | B | |
| AR245730A1 | Argentina | A1 | |
| GR880100868A | Greece | A | |
| LT2618B | Lithuania | B | |
| MD207B1 | Republic of Moldova | B1 | |
| MD207C2 | Republic of Moldova | C2 | |
| BG60768B2 | Bulgaria | B2 | |
| SE503267C2 | Sweden | C2 | |
| GEP19960479B | Georgia | B | |
| JP2785023B2 | Japan | B2 | |
| DE19975073I1 | Germany | I1 | |
| NL300001I1 | Netherlands (Kingdom of the) | I1 | |
| NL300001I2 | Netherlands (Kingdom of the) | I2 | |
| DE3844408C2 | Germany | C2 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased due to non-payment of the annual feeCeasedELJ | ELJ |
Numbers
- Publication, DOCDB
- 396787
- Publication, EPODOC
- AT396787B
- Application
- 318788
- Application, DOCDB
- 318788
- Application, EPODOC
- AT318788
Titles2
- German
- NEUE DERIVATE DER 17BETA-OH 19-NOR-STEROIDE, DIE AN STELLE 17ALPHA SUBSTITUIERT SIND, IHR HERSTELLUNGSVERFAHREN, IHRE ANWENDUNG ALS MEDIKAMENTE UND PHARMAZEUTISCHE ERZEUGNISSE, IN DENEN SIE ENTHALTEN SIND
- English
- NEW DERIVATIVES OF THE 17BETA-OH 19-NOR-STEROIDS SUBSTITUTED TO 17ALPHA, THEIR MANUFACTURING PROCESS, THEIR APPLICATION AS MEDICAMENTS AND PHARMACEUTICALS IN WHICH THEY ARE CONTAINED
Classification
- CPC, 10
- C07J41/0033
- C07J41/0083
- A61P25/20
- A61P3/04
- A61P3/06
- A61P3/08
- A61P43/00
- A61P9/10
- A61P9/12
- A61P3/10
- IPC, 11
- A61K31 57
- A61K31 575
- A61P3 04
- A61P3 06
- A61P3 08
- A61P3 10
- A61P9 10
- A61P9 12
- A61P25 20
- A61P43 00
- C07J41 00
